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Abstract
Only a small fraction of large genomes such as that of the human contains the functional regions such as the exons,
promoters, and polyA sites. A platform technique for selective enrichment of functional genomic regions will enable
several next-generation sequencing applications that include the discovery of causal mutations for disease and drug
response. Here, we describe a powerful platform technique, termed ‘‘functional genomic fingerprinting’’ (FGF), for the
multiplexed genomewide isolation and analysis of targeted regions such as the exome, promoterome, or exon splice
enhancers. The technique employs a fixed part of a uniquely designed Fixed-Randomized primer, while the
randomized part contains all the possible sequence permutations. The Fixed-Randomized primers bind with full
sequence complementarity at multiple sites where the fixed sequence (such as the splice signals) occurs within the
genome, and multiplex amplify many regions bounded by the fixed sequences (e.g., exons). Notably, validation of this
technique using cardiac myosin binding protein-C (MYBPC3) gene as an example strongly supports the application and
efficacy of this method. Further, assisted by genomewide computational analyses of such sequences, the FGF
technique may provide a unique platform for high-throughput sample production and analysis of targeted genomic
regions by the next-generation sequencing techniques, with powerful applications in discovering disease and drug
response genes.
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Introduction
The large scale sequencing of thousands of genomes from
disease cohorts by the next generation sequencing (NGS)
techniques are expected to uncover causal gene mutations [1–5].
As the large-scale NGS capabilities and logistics are becoming
established, target enrichment of genomes will be a boon for
specific applications involving massive parallel scanning of
targeted genomic regions [6]. The scalable technique we describe
in this report, termed Functional Genomic Fingerprinting (FGF), is
capable of selectively amplifying and screening any genomic
functional regions bounded by short repeated sequences such as
the exons that are bordered by splice signals, or regions
surrounding the regulatory elements (e.g., promoters and polyA
sites) within a genome. Whole or selective subsets of exomes,
promoteromes or sequences such as the lariat sites or exon-splice
enhancers can be isolated by this technique. As considerable
fraction of causal mutations is located within genetic regulatory
regions [7–13], FGF may provide a powerful technique for causal
mutation discovery.
In this paper, we describe the computational analysis of the human
genome for testing the feasibility of the FGF method. We then apply
the FGF method to a small subset of exons in the cardiac myosin
binding protein-C gene (MYBPC3) for demonstrating that FGF is
capable of multiplex amplifying exons from the genome. Automation
of FGF method might be a powerful target enrichment strategy for
selective genomic functional regions, which may have potential
applications in medical, agricultural and biotechnology fields. If this
technique is demonstrated, then it should be currentlyfeasibleto scale
it to sequence selective functional regions of the genome, such as the
exome or promoterome, on NGS platforms, and compare them
between cohorts of 1000 patient versus 1000 normal individuals,
enabling the identification of causal genes. As a targeted polymerase
chain reaction (PCR) based technique that largely avoids non-
specificity, FGFmay be a viableand cost-effective alternative to array
and solution based hybridization enrichment technologies.
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Design of Fixed-Randomized (FR) primers
The exceptionality of FGF lies in its ability to focus on the
sequences of the functional regions of a genome such as the
promoter, polyA site, branch point site, and the 59 and 39 splice-
junction signals. This ability largely depends upon the unique
design of the primers employed. The consensus sequences of
regulatory signals in eukaryotic genes are typically short,
approximately 6–12 bases in length [14] (Figure 1). FGF exploits
such short-sequence feature of the regulatory sequences with
Fixed-Randomized (FR) primers, which are each made up of one
fixed (F) and one randomized (R) sequence part. The F sequence
consists of 6–12 bases that are complementary to a target
consensus sequence. The R part contains all possible sequence
combinations, allowing for complete complementary base pairing
over the entire length of the FR primers at multiple locations
wherever the fixed sequence occurs in a template DNA. These FR
primers are thus uniquely designed to bind at multiple locations of
a given regulatory sequence throughout the genome, while
providing a full, ideal length primer capable of binding at each
of these locations. The power of the FR primers is that the correct
fully complementary sequence primer will selectively bind at each
of the target site, as only that primer species will be able to bind at
a high melting temperature (Tm) used in the PCR reaction. Thus
an FR primer set contains a series of primers, each of which
contains the same F portion and a variable R portion of a given
length with all possible sequence variations. Figure 2 depicts the
design and the synthesis of an FR primer set with a five-base fixed
sequence and a three-base variable sequence. After three serial
additions of all the four bases (A, T, G or C) at each synthetic step
to a fixed five base sequence, the resultant FR primer set contains
all of the possible 64 triplets attached to the fixed ATCTG
sequence.
The basic principles of the FGF technique for multiplexed
amplification of exons in the human genome are summarized in
Figure 3. Note that the donor and acceptor splice signal sequences
of an exon are set as the F portions of two different FR primers.
Hence selected human genomic DNA fragments are amplified
with this pair of ‘splice-signal’ FR primers. In practice, this scheme
produces multiplexed amplification of many exons from different
genes in the human genome and the amplified products can be
easily detected by electrophoresis. Genetic variants can be
identified with comparative FGF in which FGF is conducted with
both a test genome (i.e. from an individual with a disease or
genetic trait of interest) and normal genomic DNA, using a series
of ‘splice-signal’ FR primers with varying sequences, and the
resultant polymerase chain reaction (PCR)-amplified fragments
from each are displayed side by side. Differing fragments can then
be sequenced to identify specific mutations.
Computer modeling of multiplexed exon amplification of
the human genome
We conducted a detailed computer simulation, wherein the
whole human genome sequence was PCR amplified with the 59
and 39 splice signal FR primers. The FGF ePCR software program
searches both strands of the genomic sequence and reports all the
locations of the forward and reverse primer sequences. It then
reports the locations of the fragments (amplicons) under a specified
length that are bounded by the forward and reverse primers. The
program then identifies whether each fragment represents an exact
exon, part of an exon, intronic or intergenic sequence by
Figure 1. The consensus sequences of genetic regulatory
elements. The consensus sequences of the gene regulatory regions
are usually 6–12 bases long. Since the donor (5’) splice signal reads into
the intron, its complementary sequence is used to design a primer that
will read into and amplify the exon. In this example, the fixed sequence
is on the 5’ end, and the randomized sequence is on the 3’ end of the
FR primer.
doi:10.1371/journal.pone.0011138.g001
Figure 2. Design of an FR primer. To a core fixed sequence (ATCTG),
a series of Ns (A, T, G and C) are added in equimolar concentrations at
each step of the oligo-nucleotide synthesis. This process generates all
possible sequences of length n, when n bases are randomized, such
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Refseq Human Genome Build (NCBI 36.1).
The length of the fixed primer sequence determines the
probability and thus the frequency of its occurrence within a
genome. We conducted a simulation of PCR amplification of the
human genome with FR primers containing different numbers of
fixed and randomized bases. For the size of the human genome
(3.2 billion base pairs), a given sequence of 15–16 bases in length
occurred once, on average. Our results indicated that a fixed
length of 13 or more bases in the FR primer pairs generated either
none or only one or two fragments. They showed that a fixed
length of 9–12 bases in the FR primer pairs generated many
fragments in the desired range of 10–100 fragments, ideal for
fingerprint analysis (results not shown). These primer lengths were
also the length range of splice signal consensus sequences, and
were ideal for amplifying exons from the human genome when
used in conjunction with a randomized sequence length of
approximately 6–8 bases. Furthermore, the results indicated that
approximately 60–75% of the amplified fragments matched or
overlapped with exons. However, given that the majority of
human genes annotated in RefSeq are computer predicted
(,6,000 genes are experimentally validated and ,21,000 genes
are predicted) [15], the fraction of ePCR exons matching the real
exons will be higher if the number of genes in the genome will be
found to be higher in the future. In addition, the probability that
splice signals border true exons is higher in smaller genomes, such
as those of the Arabidopsis, Drosophila and Plasmodium, because
the fraction of intron sequences within these genomes is
considerably less [16]; therefore the vast majority of the fragments
amplified by FGF primers must be real exons.
The lengthofthefixed primersequence determinestheprobability
and thus the frequency of its occurrence within a genome. While the
primer lengths between 9–12 bases will generate between 10–100
fragments that is ideal for fingerprint analysis within the human
genome (3.2 billion base pairs), a higher coverage of exons is desired
for NGS applications. This should be feasible by decreasing the fixed
length of the primers by even one or two bases, and/or by
incorporating variable bases within the fixed sequence of the FR
primer as appropriate to the functional element.
Feasibility testing of FGF
The objective of this study was to test whether the FR primers
would amplifyexons from the human genomic DNA according to the
expected results predicted by the FGF technique. We used exons 7
and 8 of the MYBPC3 gene (containing 35 exons), which were also
examined by ePCR computer simulation (see above). MYBPC3 is a
thick filament associated protein in the cardiac sarcomere which
contributes 2% of the total heart mass. Mutations in MYBPC3 can
cause hypertrophic cardiomyopathy that is characterized by cardiac
hypertrophy, myocyte disarray, contractile dysfunction and sudden
death. Importantly, mutations in this gene have been linked to
hypertrophic cardiomyopathy in more than 60 million people
worldwide. We defined a series of FR primers based on the donor
and the acceptor splice signal sequences at the extreme ends of these
exons, such that the specified number of bases at the 39 end of these
primers were replaced by a series of random nucleotides (Figure 4).
The randomized sequence at the 39 end of the primer is expected to
afford the specific selection of the correct complementary sequence
from among the population of primer sequences, which contain all of
the possible sequences of the length of the randomized sequence
during PCR amplification. Further systematic studies will delineate
thediff erenceinusingthefi x edsequen ceatth e59end orthe39endof
the FR primer. While the full-length primer pair should amplify only
the expected fragment, encompassing the two exons and the
intervening intron (exon 7 – intron 7 – exon 8), the FR primer
pairs should amplify increasing numbers of exons as the number of
fixed bases is decreased and the number of randomized bases (Ns) is
increased.
To test these predictions, human genomic DNA was PCR
amplified with the full-length primers and the accompanying series
of splice signal FR primers (sequences are shown in Table 1). Note
that the concentrations of the primers used were increased
progressively as the number of Ns increased to compensate for
the degeneracy of the 39 bases. The PCR products were resolved
Figure 3. Multiplexed amplification of exons by splice signal FR primers. The FR primers for the donor (59 splice signal) and the acceptor (39
splice signal) splice sequences bind the exons with complementary base pairing over the entire length of the primers, by virtue of the presence of all
the possible sequences within the randomized sequence portion of the FR primer. Only the specific primer molecule from the FR primer population is
expected to bind selectively with full complementarity at the fixed sequence target site at a high Tm condition. The FR primers amplify multiple
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the full-length primer pair, in which the primer was 100%
complementary to the donor sequence of exon 7 and the acceptor
sequence of exon 8 with no Ns, resulted in the expected single, 438
base PCR product (lane 1). When 2N FR primers were used (lane
2), such that the primer preparation contained all 16 possible di-
nucleotide sequences at their 39 ends, amplification of the exon 7–8
fragment was observed together with amplification of two
additional fragments. The two new fragments presumably
correspond to unknown exon regions of other genes. Likewise,
when 4N FR primers were used (lane 3), such that primers
contained all the 256 possible tetra-nucleotides at their 39 ends,
four additional exons were seen in addition to the product seen
with the full length fixed primers. Further increasing the number
of random nucleotides (5Ns and 6Ns) resulted in more bands (7
and 9 fragments, respectively). Importantly, the expected exon
fragment amplified by the full-length primer pair was present in all
of the lanes, and the fragments generated by each FR primer set
always represented a subset of fragments generated by FR primers
with a greater number of Ns. Thus by decreasing the number of
fixed primer bases and increasing the number of Ns in an FR
primer set, one can amplify an increasing number of new exon
fragments from other genomic regions.
We employed our computational ePCR FGF simulation (see
above) to predict the exon amplicons generated by the splice signal
FR primer pairs shown in Table 1. We also developed a computer
program for simulating the electrophoretic gel pattern of the
electronic PCR amplified fragments. This gel pattern was
compared with the actual gel image of the amplified fragments.
There was less number of fragments predicted by the simulation
than those in the experimental gel when we used the FR primers
with 6Ns on the 39 end (Table 1). However, it was possible that,
because the FR primers used in the experiment were long (59
primer: 19 bases; 39 primer: 21 bases), some of the bases on the 59
end of the primers may not have bound with the template DNA.
When we removed four bases from the 59 end of the forward FR
primer and 3 bases from the 59 end of the reverse FR primer (the
primer sequences used were: 59 splice signal: AGAGGC-
CATNNNNNN; 39 splice signal: TCACTATGGAGANN-
NNNN), the match between the simulated and experimental
fragments was the maximum. Between the 11 computer predicted
fragments (lane 6) and 10 experimentally amplified fragments (lane
5), eight fragments matched within the length range of 100–1500
bases (Figure 4). The very high fraction of matching fragments
(80%) showed that the FR primers containing 59 and 39 splice
signal sequences specifically amplify exons from a given genome.
Discussion
The above results indicate that multiplexing of exons using FR
primers is feasible. The consistent increase in the number of
Figure 4. Multiplex genome-wide exon amplification based on
MYBPC3 gene exons 7 and 8. The human genomic DNA was PCR-
amplified under standard conditions at 58uC with primers designed
from the donor (59) splice signal sequence (from exon 7) and the
acceptor (39) splice signal sequence (from exon 8) of the MYBPC3 gene.
It was also amplified by the same FR primer pairs with decreasing
number of fixed bases and increasing number of random bases (Ns) as
shown in Table 1. The expected fragment (438 bases for the combined
exon 7, intron 7 and exon 8) is present in all the lanes, and the number
of fragments amplified increased with increasing Ns in the FR primers.
M1 & M2 are marker lanes. Lane CS shows the computer simulated exon
fingerprint obtained with the same primers used for lane 5, with four
bases removed from the 59 end of the forward primer and three bases
removed from the 59 end of the reverse primer (see text).
doi:10.1371/journal.pone.0011138.g004
Table 1. FR Primers used in the amplification experiments shown in Figure 4.
Lane Forward primer /Reverse primer
Number of random
nucleotides





1 ACCCAGAGGCCATGGGCAC/CTATCACTATGGAGAGGGACC 0 N 12.5 pmol 1
2 ACCCAGAGGCCATGGGCNN/CTATCACTATGGAGAGGGANN 2 N 200 pmol 16 (16)
3 ACCCAGAGGCCATGGNNNN/CTATCACTATGGAGAGGNNNN 4 N 1400 pmol 256 (116)
4 ACCCAGAGGCCATGNNNNN/CTATCACTATGGAGAGNNNNN 5 N 2000 pmol 625 (160)
5 ACCCAGAGGCCATNNNNNN/CTATCACTATGGAGANNNNNN 6 N 2000 pmol 1296 (160)
aExcess FR primers required theoretically for each specific primer sequence within the primer population to be the same as in the standard PCR reaction compared to
the actual excess used in the experiment.
doi:10.1371/journal.pone.0011138.t001
Genomewide Exon Enrichment
PLoS ONE | www.plosone.org 4 June 2010 | Volume 5 | Issue 6 | e11138bands observed when the number of fixed primers was decreased
and the number of randomized bases was increased in the FR
primers suggests that the FGF technique should be generally
applicable to multiplex amplify exons from a genome, by using
FR primers based on different splice signal sequences. By
comparing the same set of amplification products from different
samples, sequence differences such as point mutations within the
splice signals, or deletion mutations within any of the multiplexed
amplified exons, can be revealed by the size shift or the absence
of specific fragments. Thus the technology may be broadly
applicable for the detection of disease and drug-response gene
markers in humans or for the detection of trait associated gene
markers in cultivated plants. Because the majority of mutations
associated with diseases or traits are within gene functional
regions, such as splice signals, promoters, polyA sites, branch sites
and exons [7–13], this technique has the potential to be highly
specific for detecting disease, adverse drug-response and trait-
associated mutations. FGF largely avoids the complication of the
high frequency of non-specific inter-genomic differences within
non-genic regions that is encountered with other techniques, such
as the AFLP [17–21] and RAPD [22]. FGF thus provides the
most complexity reduction focusing specifically on the relevant
regions required in the analysis of a large genome such as the
human. Recently, array and solution based hybridization
techniques have been developed for target sequence enrichment
[23–25]. The specific PCR based FGF technique may be a viable
and cost-effective alternative to array and solution based
hybridization enrichment technologies, avoiding the non-speci-
ficity problems inherent in hybridization.
With FGF, the number of exonic fragments generated can be
controlled by adjusting the number of fixed versus randomized
bases within the FR primer. Decreasing the length of the fixed
sequence and increasing the number of randomized bases,
increases the number of binding sites within the genome, and
thus the number of fragments amplified. The FGF method is ideal
for analysis of exons from the human genome using automated
capillary DNA sequencing equipment (e.g. ABI or APB), as the
vast majority of exons (.98%) in the human genome are shorter
than 750 bases [16]. FGF is also amenable to high throughput
analysis of exons, as automated gel analysis equipment can process
as many as 10,000 exons per gel run. Thus, with only 30 runs, all
of the 300,000 exons within the human genome can be processed.
Alternatively, multiplexed exons (or desired regions) can be pooled
and sequenced on an NGS platform using barcoded sequences
from multiple patients. The data collection and comparative
fingerprint analysis can be automated for comparing the normal
and the disease genomes.
With the appropriately designed FR primers, the FGF method
can also be applied for the multiplexed genome wide amplification
of any targeted regions, such as promoters (e.g, by amplifying the
regions between the promoter and the end of the first exon),
branch-point sites (e.g., the region between the lariat and the start
or the end of the immediately downstream exon), and polyA sites
(e.g., the region between the start of the last exon and the polyA
site). With one splice signal FR primer directed towards the intron,
and a second arbitrary fixed sequence primer, intron sequences
adjacent to the exons can be analyzed genome-wide. Genome-
wide computational analyses of functional elements such as the
promoters should enable the selection of subsets of FR primers for
comparison between disease and normal cohorts. FGF can also
generate a fingerprint of a genome with any sequence of interest
that frequently repeats within the genome. It may be used to clone
a library of exons from unsequenced genomes for subsequent
sequencing, which may help to identify genes of interest. With
arbitrary sequences that may repeat within a genome as the fixed
sequences, different variations of FR primers can generate useful
fingerprints. This method has the potential for many applications
that explore directly the targeted regions of a genome, and may
enable fast and relatively inexpensive detection of causal mutations
underlying many uncharacterized human illnesses. Additionally,
FGF has several applications in microbial genomics such as
pathogenic detection and strain identification.
In conclusion, the results demonstrate that genome wide
amplification of multiplexed exons and other targeted regions
from the human genome is feasible. The high probability that
genes bearing causal mutations of diseases and adverse drug effects
are contained within these targeted regions gives the FGF
technique momentous practical utility in medicine, diagnostics
and agriculture. While the current genome wide genotying
techniques have not yet uncovered the disease modifying and
drug response genes and their relevant causal mutations, the FGF
technique may prove to be capable of identifying them effectively.
Moreover, this technique is amenable to automated high
throughput processing and rapid genome-wide screening of large
targeted data. The FGF technique is scalable and can be
integrated with the NGS and microarray techniques [26,27],
enabling rapid sequencing of the FGF fragments (e.g., genome
wide exons), thereby allowing faster direct comparisons of the
targeted regions between the disease and the normal genomes. In
addition to its capability to compare fingerprints of functional
regions from different genomes for studies including genotypic
differences among species, FGF can be an effective front-end
target enrichment strategy for NGS platforms, with a variety of
biomedical and agricultural applications.
Methods
Primer design and preparation
Fixed-Randomized (FR) primers were designed based on the
concept described in the text. The fixed base sequence of a given
length was synthesized first, and randomized bases were
sequentially added at the end of a fixed base sequence with equal
concentrations of the A, T, C, and G at each addition. Different
FR primers with differing lengths of fixed and randomized
sequences were synthesized as required. Primer 3 software [28]
was used for primer design.
Polymerase Chain Reaction
As an example, the DNA fragment representing Exon 7 –
Intron 7 – Exon 8 – Intron 8 from the human gene MYBPC3 was
used in this experiment. The forward and the reverse primer
sequences and the details of the PCR reactions are as shown in the
Table 1. The bases at the 39 end of the primers were replaced by
increasing number of Ns, concomitantly reducing the length of the
fixed bases. The PCR experiment was conducted at a Tm of 58uC
in a reaction volume of 125 micro-liters. The concentrations of the
primers were increased in the different PCR reactions with
primers containing Ns as shown in the Table 1. Fifty nanogram of
human genomic DNA was used as the template DNA. PCR
reaction mixtures contained in a volume of 50 ml: 50 ng of
genomic DNA, 100 mM Tris-HCl (pH 8.3), 15 mM MgCl2,
500 mM KCl, 1 mg/ml gelatine, at 20uC, 100–150 pmoles of
each primer, all four dNTPs at 200 mM (Roche), respectively, and
1 U of Taq-DNA polymerase (Fisher Scientific). Each PCR
reaction was initially denatured at 94uC for 4 min. Cycling
conditions (BioRad) were 94uC (30 sec) for denaturation; 55uC
(30 sec) for annealing and 72uC (60 sec) for extension. After 38
cycles PCR was terminated by a final synthesis at 72uC for 8 min.
Genomewide Exon Enrichment
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of FR primers
The complete procedure involved in computational analysis of
the genome is the subject of a separate publication (In
preparation). A brief description follows. The human genome
sequence was searched for the occurrence of the fixed sequences of
a given FR primer pair (e.g., an exon FR primer). The output
sequences were matched with the NCBI annotations of exons that
contained the computer identified FR splice signals on either or
both sides. The fractions of the intron or intergenic sequences
containing the computer identified splice signals were also
computed. The fraction of the computer amplified exons using a
given splice signal FR primer pair that matched with the actual
exons within the genome was computed from the above fractions.
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